FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, and the grace periods for compounders ended by May 2025. What remains is a narrow path: a compounded version made for one patient, on a prescription, that is not a copy of the approved drug.
FDA does not test or approve these products before they are sold. As of May 31, 2026 it had received 990 adverse event reports about compounded semaglutide and more than 730 about compounded tirzepatide. This page sets out the agency's decisions by date, the test it uses for a copy, what it has found, and what a buyer can check.
Is compounded semaglutide still allowed in 2026?
Only in limited cases. During the shortages, federal law let pharmacies and outsourcing facilities make what were in effect copies of Wegovy, Ozempic, Zepbound and Mounjaro. Both shortages have ended, and FDA's position, restated on April 1, 2026, is that semaglutide and tirzepatide are neither on its shortage list nor on the list of bulk substances that outsourcing facilities may use.2
503A and 503B are the two sections of federal drug law that cover compounding. They are explained in the next section.
The last entries are still open. On April 30, 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it had found no clinical need for outsourcing facilities to compound them from bulk substances. It took public comments until June 29, 2026 and said it would consider them before a final determination.3
Who may still compound it, and under what rule?
Federal law has two kinds of compounder, and the answer differs for each.2
| State-licensed pharmacy or physician (503A) | Outsourcing facility (503B) | |
|---|---|---|
| First condition | The drug is compounded for one patient, on a prescription | A bulk substance may be used only if it is on the 503B bulks list or the drug is on the shortage list |
| Copies | May not make copies of an available approved drug regularly or in inordinate amounts | The same list rule decides |
| Semaglutide and tirzepatide today | Possible only when the product is not essentially a copy | Neither is on the bulks list or the shortage list |
| Adverse event reports to FDA | Not required by federal law | Not covered by that exemption |
FDA, policies for compounders, entry of April 1, 2026; reporting duty as described on FDA's GLP-1 concerns page.1,2
FDA keeps one tolerance for small-scale work. It has said it does not intend to act against a compounder that fills four or fewer prescriptions of a copy in a calendar month.2 A compounder filling hundreds of such prescriptions a month is outside it.
What makes a compounded product an illegal copy?
FDA's guidance uses three conditions and one exception. A compounded product is essentially a copy of a commercially available drug when it has the same active ingredient, in the same, a similar or an easily substitutable strength, and the approved drug can be given by the same route. The exception is a change that the prescriber determines, and documents, makes a significant difference for an identified patient.2
This follows the wording of FDA's April 2026 statement. It is a reading aid and not legal advice; FDA and state boards of pharmacy decide individual cases.
Adding a vitamin does not get around the test. FDA gives the example itself: semaglutide combined with vitamin B12 may still be essentially a copy when it is given the same way and the amounts of both are within 10% of the strengths of the commercially available products.2
The agency has also said that the safety and effectiveness of combining semaglutide with other ingredients, among them B12, B6, L-carnitine and NAD, has not been established.4
What has FDA found in compounded GLP-1 products?
The starting point is what FDA does not do. Compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed.1 Its list of concerns comes from reports, complaints and its own investigations.
The wrong form of the ingredient
Some products sold as semaglutide contain semaglutide sodium or semaglutide acetate. These salts are different active ingredients from the one in the approved drugs. FDA says it has no information on whether they behave the same way and knows of no lawful basis for using them in compounding.1
Labels that are not true
FDA has found compounded semaglutide and tirzepatide with false information on the label. In some cases the pharmacy named on the label does not exist. In others the label names a real licensed pharmacy that did not make the product. One adverse event report concerns such a product labeled as tirzepatide: redness, swelling, pain and a lump at the injection site.1
Vials that arrive warm
Injectable GLP-1 drugs need refrigeration. FDA has received complaints of compounded products arriving warm or with too few ice packs, and recommends not using any injectable GLP-1 drug that arrives that way.1
Vials used for too long
A vial with several doses should be used within 28 days of the first use, because the risk of contamination rises after that. FDA tells consumers to discard the vial at 28 days even if medicine remains and even if the compounder's instructions allow longer, and to use a new sterile needle and syringe every time.1
Doses beyond the label
FDA has adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed beyond the approved labels: more in one dose, doses taken more often, or doses raised faster than the label's schedule. Some of the patients sought medical attention for nausea, vomiting, diarrhea, abdominal pain and constipation.1
Ingredients from uninspected makers
FDA has set up an import alert to stop GLP-1 active ingredients with potential quality problems at the border. It does not apply to ingredient makers that appear, from an FDA inspection or other evaluation, to meet its manufacturing standards.1
How many problems have been reported?
A report means that an event followed the drug, not that the drug caused it. Poison center figures cover all GLP-1 medicines, approved and compounded.
FDA is careful about what these numbers mean. Many of the reported events look like the known side effects of the approved drugs, and it is not always possible to tell whether the product caused the event. It also says the count is probably too low, because state-licensed pharmacies that are not outsourcing facilities are not required to send it adverse event reports.1
Poison centers show the growth of the whole market. A study of the National Poison Data System found 10,033 exposures to GLP-1 medicines from 2012 to 2023, with 6,920 of them after July 2021. Most were unintentional dosing errors with mild stomach symptoms, and the share treated in or referred to a health care facility rose from 23.0% to 33.5%.9
Why are dosing errors a particular risk with vials?
Because the patient measures the dose. The approved injections are dosed in milligrams, at standard concentrations, in pens. A compounded vial comes with a syringe and an instruction that may be written in units, milliliters or milligrams, and concentrations differ between compounders and even between products from one compounder.4
In July 2024 FDA reported overdoses from exactly this: patients drawing five to 20 times the intended dose, and prescribers miscalculating by five to 10 times. Some patients needed hospital care.4
How can I tell a risky seller?
FDA publishes a list of warning signs for companies that sell these drugs through telehealth. Tap the ones that apply.1
Keep the vial label and each dose on record in the app.
Open the appBeyond compounders there is a market with no pharmacy at all. A 2024 study searched for semaglutide sold online without a prescription. Of 317 search results that led to online pharmacies, 134 pointed to 59 illegal pharmacy websites, and the 30 most visited of those domains had drawn more than 4.7 million visits in three months.5
The researchers ordered from six of the illegal sites. None of the three Ozempic pens they paid for arrived. Three vials did. Each held 29% to 39% more semaglutide than its label stated, every sample contained endotoxin, a toxin from bacteria, and measured purity was 7.7% to 14.4% against the 99% printed on the labels.5
Three vials bought without a prescription
FDA's advice for buying online is short: get a prescription from your doctor and fill it at a state-licensed pharmacy.1
How many people use compounded versions?
There is no national count, but three studies give a sense of scale. In a national survey of 440 adults who had stopped a GLP-1, 9.8% had got it from a compounding pharmacy and 9.1% from an internet source. Those two groups were more likely than pharmacy customers to say they stopped because the drug did not seem to work: 17.5% against 6.6%.6
In a review of 288 medical charts of people who stopped semaglutide or tirzepatide for obesity, 2.4% had stopped in order to switch to a compounded product.7
Compounded use is also hard to see in records. An analysis of clinical notes found a compounded product mentioned for 1,696 patients, and for about half of them, 50.8% on semaglutide and 57.9% on tirzepatide, the first mention came on or before the first recorded prescription.8 For those patients the compounded product came before anything in the prescription record.
How large is the price gap now?
Lilly now sells Zepbound directly at cash prices. On LillyDirect the KwikPen is listed for self-pay at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg when the prescription is refilled within 45 days.10 Enter what you pay for a compounded product to see the difference.
The app tracks each fill and what it cost.
Open the appLilly's self-pay prices as listed on November 20, 2026. The $449 price needs a refill within 45 days; otherwise 7.5 mg is $499 and 10 mg to 15 mg are $699. The starting figure of $199 is a placeholder: replace it with your own price.
The Zepbound cost page covers insurance, the savings card and the full year.
What about retatrutide and "research use only" vials?
Neither can be lawfully compounded or sold for people. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. They are not part of any approved drug and have not been found safe and effective for any condition. The agency has warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide.1
It has also warned companies that sell semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled "for research purposes" or "not for human consumption" while supplying dosing instructions to consumers. FDA urges people not to buy them: their quality is unknown.1
What should I ask before using a compounded product?
The questions below come straight from the concerns above.
Which pharmacy made it, and is that pharmacy licensed in my state? The name on the label should match a pharmacy that exists and that says it made the product.
What is the active ingredient? Semaglutide or tirzepatide, not a salt such as semaglutide sodium or acetate.
What is the concentration in mg per mL, and what is my dose in mg? An instruction in units alone is not enough.
Why a compounded product and not the approved one? Under FDA's test there should be a documented difference that matters for you.
How was it shipped, and when was the vial first opened? Warm on arrival means do not use it; 28 days after first use means discard it.
What can this page not tell you?
It cannot say whether a particular vial is safe. Nobody outside the pharmacy that made it can, which is the point FDA makes about the absence of pre-market review.
The legal position is still moving. The proposal on the 503B bulks list had not been reported as final in the FDA statements cited here, and state boards of pharmacy apply their own rules on top of federal law.
Report counts are a floor. They depend on someone choosing to file a report, and most compounders are not required to.
Short answers to common questions
Is compounded semaglutide legal in 2026?
In narrow cases. A state-licensed pharmacy may compound for an individual patient on a prescription when the product is not essentially a copy of an approved drug. The shortage that allowed copies ended on February 21, 2025, and outsourcing facilities may not use bulk semaglutide because it is on neither the shortage list nor the 503B bulks list.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It is not FDA approved, and FDA lists a company's claim that a compounded drug is the same as an approved one as a warning sign. Some compounded products contain salt forms that are different active ingredients.
Is compounded tirzepatide still available?
The tirzepatide shortage was declared resolved on December 19, 2024, and the grace period for outsourcing facilities ended on March 19, 2025. The same narrow rule for individual prescriptions applies as for semaglutide.
Is semaglutide with B12 allowed because it is different?
Not on that ground alone. FDA's own example says a combination of semaglutide and vitamin B12 may still be essentially a copy when the strengths are within 10% of the approved products and the route is the same.
How many adverse events have been reported?
As of May 31, 2026, FDA had received 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide, and says the real number is likely higher.
How long can I use a compounded vial?
FDA recommends discarding a vial that holds several doses 28 days after the first use, even if medicine is left and even if the compounder's instructions say it can be used for longer.
Can retatrutide be compounded?
No. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law.
How this page was built
Every statement about the rules is taken from three FDA documents read on November 20, 2026: the agency's page on unapproved GLP-1 drugs, last updated October 1, 2026; its running statement on policies for compounders, with entries from December 2024 to April 2026; and its press announcement of April 30, 2026. The copy test repeats the conditions in the April 2026 entry.
The price calculator multiplies the monthly difference by 12 and divides it by 4.345 for the weekly figure. Zepbound prices are Lilly's self-pay prices for the KwikPen on the date above. The compounded price is whatever you enter.
Sources
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, April 30, 2026. fda.gov
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Content current as of July 26, 2024. fda.gov
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res 2024;26:e65440. doi:10.2196/65440
- DiStefano MJ, Zon J, Olson EG, Levy JF, Anderson GF, Alexander GC. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: a national survey. J Manag Care Spec Pharm 2026;32:903-910. doi:10.18553/jmcp.2026.32.8.903
- Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity (Silver Spring) 2025;33:2296-2303. doi:10.1002/oby.70058
- Varma G, Murugadoss K, Kurian ME, et al. Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records. Biol Methods Protoc 2026;11:bpag035. doi:10.1093/biomethods/bpag035
- Miller J, Miller R, Varney SM, Han D. National poison center trends in GLP-1 receptor agonist exposures following FDA approval for weight loss. J Med Toxicol 2026;22:275-285. doi:10.1007/s13181-026-01121-z
- Eli Lilly and Company. Zepbound (tirzepatide) on LillyDirect: self-pay prices. Read November 20, 2026. lilly.com
Related analyses
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy cost: what the pen and the pill cost with insurance, without it, and over a year
Alcohol on a GLP-1: what the labels say, what counts as a drink, and what five studies found
Bowel obstruction and ileus on a GLP-1: six studies and four labels
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider